The analysis of blood tumor treatment is the most preferred.

Hematoma tumor is a general term for a large class of malignant tumors originating in the hematopoietic system. According to the statistical ranking of common malignant tumors in China, acute leukemia and lymphoma in blood tumors are ranked in the top ten, and the incidence rate has been on the rise overall in recent years. Compared with developed countries such as the United States and Japan, there is still a significant gap in the five-year survival rate of myeloma, lymphoma and leukemia patients in China. In the case of lymphoma, according to The Lancet 2018 survey data, the five-year survival rate of lymphoma patients in China is about 38.3 percent, compared with 57.3 percent in Japan and 68.1 percent in the United States. Another common blood tumor myeloma has a five-year survival rate of about 24.8 percent in our patients and 46.7 percent in the United States.
in recent years, the rapid development of blood tumor treatment technology, the emergence of new drugs, including targeted drugs, cells and immunotherapy, so that blood tumor patients get higher remission and longer survival. How do patients with blood tumors choose the right treatment for them? What diseases will be encountered before and after hematopoietic stem cell transplantation? On Friday, April 17, from 17:30 to 18:30 p.m., the top tumor names in the National Cancer Prevention and Prevention Publicity Week series of "People's Famous Medical" live-streamed the second session, inviting the Beijing Heathcote Foundation Supervisor, The Chinese Society of Clinical Oncology (CSCO) And Ma Jun, director of the Harbin Institute of Blood Diseases, to provide you with the best choice for blood cancer treatment.Professor Ma Jun,
, has been engaged in clinical research on blood diseases for a long time, and has been treated with serial treatment for the first time in the treatment of acute early childhood leukemia, so that 85% of patients with acute early granulocytic leukemia have been cured, which is an internationally recognized "golden standard" program. The Harbin Hematology Research Institute he led by him was the first unit to carry out hematopoietic stem cell transplantation in Northeast China, and was the center of hematopoietic tumor treatment in Northeast China, and was also one of the four major research institutes in the hematology field of china.
welcome to watch and interact, your related questions, you can also scan the qr code below into the live message, hopefully get further answers from experts.
"People's Famous Doctor - Top Oncology Special Series Live" by the People's Daily Health Times client, China Society of Clinical Oncology (CSCO), People's Daily Health Times jointly produced, Beijing Heathcote Clinical Oncology Research Foundation support. More than a hundred tumor doctors appear, the year-round online consultation and answer questions, from the Heathcote Foundation and CSCO's top oncologists will be a guest live broadcast, for cancer patients and their families to send real-time authoritative diagnosis and guidance services, to help everyone stay at home to see the famous doctor!
",""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""" The column is directed to invite the national professional discipline leaders, the leadership of the Hospital of Sanjia and the director of the department, well-known clinical experts and netizens online exchanges.
this issue of "People's Famous Medical" live broadcast by the People's Daily Health Client, Health Times, People's Video, Tencent News, Tencent Health, Tencent Medical, Tencent Video, NetEase Health, Sohu Health, Sohu Video, Baidu Health, Beijing People's Radio City Radio, Health Gas Station, Sina One Live, The National Pension Network. One live broadcast, multi-platform inter-link.
references to this article:
(1) Zhang Min, Li Guangcan, Zhang Yuling, et al. An Analysis of the Story and Mortality with Malignant Lymphoma in China Over 2003-2007% 2003-2007 China's malignant lymphoma incidence and death analysis . Chinese Oncology, 2012, 021 (003): 190-196.
(2) Zhang Yifan. 5-year survival rate trend of 18 tumors in 71 countries. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
.